Journal of Viral Hepatitis

Article	Citations
Issue Information	42
240‐week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C	40
Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working‐age adults in Madrid (Spain)	32
Issue Information	31
International disease burden of acute viral hepatitis among adolescents and young adults: An observational study	29
Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents	27
	23
Issue Information	22
Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease	21
Baseline Alpha‐Fetoprotein Elevation and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B: A Multicentre Cohort Study	21
The role of serum sphingolipids as potential biomarkers of non‐response to direct acting antiviral therapy in chronic hepatitis C virus infection	20
Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab	20
	20
Hepatitis A occurrence and outbreaks in Europe over the past two decades: A systematic review	20
Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England	19
Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine	19
Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination	18
Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues	18
Cost‐effectiveness analysis of an active search to retrieve HCV patients lost to follow‐up (RELINK‐C strategy) and the impact of COVID‐19	18
Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B	17
Temporal and geographic spreading of hepatitis B virus genotype A (HBV‐A) in Brazil and the Americas	16
A cross‐sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non‐rural communities	16
Direct‐acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment	15
Elevation of S2‐bound α1‐acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma	15
Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study	15

Issue Information	15
A Network Map of Intracellular Alpha‐Fetoprotein Signalling in Hepatocellular Carcinoma	15
	15
Sex‐related difference analyses of efficacy and safety in clinical trials of direct‐acting antivirals to treat chronic HCV genotype 1 and 3 infections	15
Reversibility of acute‐on‐chronic liver failure syndrome in hepatitis B virus‐infected patients with and without prior decompensation	14
Issue Information	14
Long‐Term Follow‐Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon‐Free and Interferon‐Based Hepatitis C Virus Treatment	14
Integration and the risk of liver cancer—Is there a real risk?	14
Infectivity of Hepatitis B Virus Surface Antigen‐Positive Plasma With Undetectable HBV‐DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?	13
Improvement of chronic HCV infection‐related depression, anxiety, and neurocognitive performance in persons achieving SVR‐12: A real‐world cohort study	13
Prevalence of hepatitis C in sexual assault survivors presenting to a SANE clinic: A descriptive analysis	13
TRPM2 regulates autophagy to participate in hepatitis B virus replication	13
Adenovirus vector encoding TPPII ignites HBV‐specific CTL response by activating autophagy in CD8+ T cell	13
Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment	13
Contribution of alcohol use in HIV/hepatitis C virus co‐infection to all‐cause and cause‐specific mortality: A collaboration of cohort studies	13
Issue Information	13
The role of treatment of hepatitis C with direct‐acting antiviral agents on glycaemic control in diabetic patients: An updated systematic review and meta‐analysis	12
Systematic Screening for Hepatitis B, C, and HIV and Linkage to Care in Patients With Mental Health Disorders Admitted to the Emergency Department	12
Issue Information	12
Viral hepatitis in pregnancy	12
Strategies to increase primary care provider capacity for hepatitis C care: The California ECHO‐PLUS study	12
Safe co‐administration of direct‐acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study	12
Clinical and histological features of patients with chronic hepatitis B virus infection in the grey zone	11
HCV hotline facilitates Hepatitis C elimination during the COVID‐19 pandemic	11
Risk of drug‐induced liver injury in chronic hepatitis B and tuberculosis co‐infection: A systematic review and meta‐analysis	11
Challenges of hepatitis B treatment in rural Sub‐Saharan Africa: Treatment initiation and outcomes from a public hospital‐based clinic in Kono, Sierra Leone	11
Baseline and on‐treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals	10
An updated assessment of hepatitis delta prevalence among adults in Canada: A meta‐analysis	10
The changing epidemiology of delta hepatitis in Türkiye over three decades: A systematic review	10
Serum HBV RNA is associated with liver fibrosis regression in HBeAg‐positive chronic hepatitis B patients treated with nucleos(t)ide analogues	10
Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection:	10
Electronic nose versus quadrupole mass spectrometry for identifying viral hepatitis C patients	10
Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver‐related complications in patients with chronic hepatitis C receiving direct‐acting antiviral agents	10
Network‐basedstrategies to combatHCV: Examining social and spatial drivers of transmission amongPWIDin New Delhi	9
Issue Information	9
	9
Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta‐analysis	9
Effect of liver steatosis on liver stiffness measurement in chronic hepatitis B patients with normal serum alanine aminotransferase levels: A multicentre cohort study	9
Epidemiological Burden of Hepatitis Delta Virus in the United States	9
A declaration from people living with hepatitis B: A call for a whole person approach	9
Epidemiology and Outcomes of Hepatitis E Virus‐Associated Hospitalisations in the United States With a Focus on Pregnancy: A Nationwide Population Study, 1998–2020	9
	9
Hepatitis E prevalence and infection in solid‐organ transplant recipients in the United States	9
Measuring stigma associated with hepatitis B virus infection in Sierra Leone: Validation of an abridged Berger HIV stigma scale	9
The immune landscape in hepatitis delta virus infection—Still an open field	8
Serum α‐fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct‐acting antiviral treatme	8
Tenofovir disoproxil fumarate on the risk of hepatocellular carcinoma in chronic hepatitis B patients with failure to preceding treatments: A nationwide cohort study	8
Does hepatitis delta virus have a preference for hepatitis B virus genotype? A systematic review of the literature	8
VirA+EmiC project: Evaluating real‐world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department	8
Cover image	8

CHB patients with rtA181T‐mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes	8
Performance of HCV core antigen and PCR testing in a predominantly genotype 3 population	8
Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States	8
The altered HLA‐DQ expression in peripheral blood T cells of chronic hepatitis B patients characterizes the function of T cells	8
Hepatitis D virus infection: Progress on the path toward disease control and cure	8
Efficacy of an eConsult service to cure hepatitis C in primary care	8
	8
Hepatitis B e antigen and e antibody in a multi‐ethnic cohort of adult chronic hepatitis B virus patients followed at a single liver unit for a period of 20 years	8
Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon‐alfa	7
Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection	7
Reply to Wang et al	7
Factors affecting long‐term changes of liver stiffness in direct‐acting anti‐hepatitis C virus therapy: A multicentre prospective study	7
Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi‐ethnic population: Universal screening is more comprehensive	7
A novel test and treat program for hepatitis C virus infection utilizing HCV core antigen testing, among police and general population, Islamabad, Pakistan, 2022	7
Issue Information	7
Long‐term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis	7
Risk factors for hepatitis C virus infection at a large urban emergency department	7
Long‐term benefits of interferon‐α therapy in children with HBeAg‐positive immune‐active chronic hepatitis B	7
Mixed‐Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis	7
Prognostic value of genotyping in hepatocellular carcinoma: A systematic review	7
	7
Mortality and morbidity related to hepatitis C virus infection in hospitalized adults—A propensity score matched analysis	7
	7
A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP‐HEPC t	7
Impact of COVID‐19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs	7
Socioeconomic Deprivation Weighs Heavily on Liver Fibrosis and Mortality After Hepatitis C Cure (ANRS CO22 Hepather)	7
Dynamic personalized prediction of the individual liver‐related risk after sustained viral response in HCV patients	7
Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™	7
Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal	7
Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct‐acting antivirals	7
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations	6
Screening rates for hepatitis B and C among low‐income US veterans: Data from the National Veteran Homeless and Other Poverty Experiences Study	6
Hepatocytes and Hepatic Stellate Cells Carry Different Levels of DNA Damage due to Their Sensitivity to Oxidative Stress in Chronic Hepatitis B	6
Reaching trans women in San Francisco for efforts to eliminate hepatitis C	6
A Qualitative Systematic Review of Barriers and Facilitators to Hepatitis B and C Programmes in Prisons	6
Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis	6
MELD score < 18 rule out 28‐day ACLF development among inpatients with hepatitis B‐related previous compensated liver disease	6
Barriers and enablers to people‐centred viral hepatitis care in Vietnam and the Philippines: Results of a patient journey mapping study	6
Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon‐based therapy	6
Phase 1 study of safety and tolerability of an oral contraceptive containing low‐dose ethinyl oestradiol combined with glecaprevir/pibrentasvir treatment in healthy premenopausal women	6
Hepatitis Delta Coinfection Rates and All‐Cause Mortality Among Hepatitis B‐Infected Veterans in the USA	6
Preferences and feasibility of long‐acting technologies for treatment of hepatitis C virus in low‐ and middle‐income countries: A survey of providers and policymakers	6
Post‐vaccination serologic testing of infants born to hepatitis B surface antigen‐positive mothers is more cost‐effective in Zhejiang Province, China: A Markov chain analysis	6
Persistent chronic immune activation in HIV/HBV‐coinfected patients after antiretroviral therapy	6
The role of hepatitis B virus core‐related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen‐negative patients	6
Maternal chronic hepatitis B virus infection and the risk of preterm birth: A retrospective cohort analysis in Chinese women	5
Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure	5
CORRIGENDUM	5
Substance use and CD4/CD8 ratio in HIV/HCV co‐infected people receiving direct‐acting antiviral treatment (ANRS CO13 HEPAVIH)	5
Sequence characterization of extracellular HBV RNA in patient plasma	5
Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real‐world analysis	5
	5
Cigarette Smoking Is Associated With Lower Chance of Hepatitis B Surface Antigen Seroclearance and Altered Host Immunity	5
Reply to ‘Assessing the hepatitis C epidemiology in Switzerland: It’s not that trivial’	5
MiRNome Profiling of Circulating Extracellular Vesicles in Patients With Chronic Hepatitis D Undergoing Pegylated Interferon Alpha Treatment	5
A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C	5
Issue Information	5
	5
Severe acute hepatitis of unknown origin in children: Is it still a mystery? What role does adenovirus play?	5
Prevalence of hepatitis B virus (HBV) and latent tuberculosis co‐infection and risk of drug‐induced liver injury across two large HBV cohorts in the United	5
The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection	5
Depletion of circ_0088046 suppressed cell growth and motility of hepatocellular carcinoma via circ_0088046‐miR‐1299‐RTKN2 ceRNA pathway	5
Shear wave elastography: How well does it perform in chronic hepatitis D virus infection?	4
	4
HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre‐ and posttreatment: a multicentre observational cohort study	4
Long‐term persistence of anti‐HAV antibody conferred by a single dose of live‐attenuated hepatitis A vaccine: Results from 17‐year follow‐up	4
Psychiatrists can treat hepatitis C	4
Genetic substructure and host‐specific natural selection trend across vaccine‐candidate ORF‐2 capsid protein of hepatitis‐E virus	4
Persistence of antibodies 5 years after hepatitis B vaccination in preterm birth children: A retrospective cohort study using real‐world data	4
	4
	4
	4
A Programme of Hepatitis C Surveillance With Active Linkage to Care (HEAL) for Inpatients in Two Tertiary Hospitals in Jiangsu, China	4
Test characteristics for combining non‐invasive liver fibrosis staging modalities in individuals with Hepatitis C virus	4
Reply to: ‘Abnormal liver function tests and coronavirus disease 2019: A close relationship’	4
Issue Information	4
Hepatitis after gene therapy, what are the possible causes?	4
Chronic viral hepatitis C micro‐elimination program using telemedicine in Guigang city	4
Impact of treatment with direct‐acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co‐infected individuals	4
Screening, Prevalence and Management of Chronic Viral Hepatitis C in Mental Health Setting: Towards the Eradication of A Forgotten Reservoir	4

Prevalence of hepatitis C among pregnant women in an Appalachian population	4
Modelling the potential impact of global hepatitis B vaccination on the burden of chronic hepatitis B in the United States	4
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy	4
A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype	4
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST‐HCV cohort	4
Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy	4
Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B‐coinfected adults in care in the United States	4
Assessing the hepatitis C epidemiology in Switzerland: It’s not that trivial	4
Closing the hepatitis C treatment gap: United States strategies to improve retention in care	4
	4
Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days	4
Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatiti	4
Dynamic Changes in ELF Score Predict Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Antiviral Treatment	4
Substance use and CD4/CD8 ratio in HIV/HCV co‐infected people receiving direct‐acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply	4
	4
Lower Serum Albumin Level: A Prospective Risk Predictor of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection	4
Hepatitis B virus–induced hepatocarcinogenesis: A virological and oncological perspective	4
Outcomes of a 1‐Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B	4
Cover Image	4
Factors influencing compliance with Hepatitis C treatment in patients transitioning from prison to community—A summary scoping review	4
Testing to sustain hepatitis C elimination targets in people who inject drugs: A network‐based model	4
Hepatitis C prevalence and elimination planning in Pakistan, a bottom‐up approach accounting for provincial variation	4
Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID‐19 pandemic	4
Issue Information	4
Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia	4
Updated Guidelines for the Prevention and Management of Chronic Hepatitis B—World Health Organization 2024 Compared With China 2022 HBV Guidelines	3
Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct‐acting antiviral agents: A scoping review	3
Associated screening for HCV and SARS‐Cov2 infection in an urban area of Southern Italy: A cohort study	3
Comparison of acknowledged hepatocellular carcinoma risk scores in high‐risk hepatitis C patients with sustained virological response	3
Accuracy of International Guidelines in Identifying Normal Liver Histology in Chinese Patients With HBeAg‐Positive Chronic HBV Infection	3
Community Pop‐Up Clinic: Cascade of Care and HCV Treatment of Vancouver's Inner‐City PWID Populations	3
Hepatitis C care cascade before and during the direct‐acting antiviral eras in New South Wales, Australia: A population‐based linkage study	3
Racial discrimination, knowledge, and health outcomes: The mediating role of hepatitis B‐related stigma among patients with chronic hepatitis B	3
Reply to: Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question	3
Hepatitis B Care and Treatment in Zanzibar, Tanzania: A Demonstration Project Following 2015 WHO Treatment Guidelines, 2017–2021	3
Impact of prior HBV, HAV, and HEV infection on non‐alcoholic fatty liver disease	3
Epidemiology, linkage to care and natural history of women of childbearing age with chronic hepatitis B: A population‐based study	3
Determining the frequency and characteristics of Hepatitis C reinfections in North East England	3
The 5‐year cumulative incidence of HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment	3
Regarding the predictive role of CXCL16 in liver inflammation in chronic hepatitis B patients	3
Neuropsychological effects of direct‐acting antiviral treatment for Hepatitis C virus subjects: A systematic review	3
A Health Systems Strengthening Approach to Address the High Burden of Hepatitis C in Pakistan	3
Real‐World Evaluation of Point‐of‐Care Testing for Hepatitis C Antibodies: Navigating Hepatitis C Elimination Effort	3
Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors	3
A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community‐based testing campaign	3
MicroRNA‐206 inhibits HCV proliferation through depressing ACC1 lipid synthesis signalling pathway	3
Expanding Hepatitis C Virus Treatment in the New Mexico State Prison System: Using the ECHO Model for Provider and Prison Peer Education	3
Evaluation of a pilot emergency department linkage to care program for patients previously diagnosed with Hepatitis C	3
Evaluating the cost‐effectiveness of hepatitis B vaccination strategies in high‐impact settings for adults	3
Response to “Reply to ‘Assessing the hepatitis C epidemiology in Switzerland: It’s not that trivial’”	3
	3
Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis	3
Efficacy and safety of pan‐genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir‐based antiretroviral therapy	3
Issue Information	3
Occult hepatitis B virus infection and current perspectives on global WHO 2030 eradication	3
Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study	3
The effects of hepatitis B virus infection on natural and IVF pregnancy: A meta‐analysis study	3
Baseline HBV‐DNA load plus AST/ALT ratio predicts prognosis of HBV‐related hepatocellular carcinoma after hepatectomy: A multicentre study	3
	3
Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B‐related cirrhosis: Multicentre real‐world observational study	3
Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study	3
Changes in the prevalence of hepatitis B and C viral infections in Sindh province, Pakistan: Findings from two sero‐surveys in 2007 and 2019	3
Chronic hepatitis C virus infections in Switzerland in 2020: Lower than expected and suggesting achievement of WHO elimination targets	3
Immunotherapy Using HBV Vaccine Pulsed DCs and Induced T‐Cells Combined Antiviral Drugs in Treatment Naive CHB Patients‐A Multi‐Centre Phase II Study	3
Incidence of primary hepatitis C infection among people who inject drugs during 2012–2020 in Athens, Greece	3
Thyroid dysfunction incidence and risk factors in Chinese chronic hepatitis B patients treated with pegylated interferon alpha: A long‐term follow‐up study	3
	3
Hepatitis C active viremia over time in an ED‐based testing programme: Impact, disparities and surveillance tool	3
A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI‐2173 in patients with chronic hepatitis B virus infection	3
Cover Image	3
Individual Heterogeneity and Trends in Hepatitis C Infection Risk Among People Who Inject Drugs: A Longitudinal Analysis	2
Correlates of chronic hepatitis B virus infection in the general adult population of China: Systematic review and meta‐analysis	2
Age, ethnicity and proximity to clinic determine retention in care of chronic hepatitis B patients	2
Misuse of the Lower Limit of Detection in HBV DNA Testing and Anti‐HBe Positive Status Will Significantly Impact the Diagnosis of Occult HBV Infection	2
	2
Research progress on detection methods for hepatitis B virus covalently closed circular DNA	2
More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL study	2
Prognosis of hepatitis E infection in patients with chronic liver disease: A meta‐analysis	2
Classification and survival prediction in early‐stage cirrhosis by gene expression profiling	2
	2
Early post‐liver transplant use of direct‐acting antivirals in naive and NS5A inhibitor‐experienced HCV patients	2
A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD	2
Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study	2
Abnormal liver function tests and coronavirus disease 2019: A close relationship	2
Patient‐reported outcomes of the Treatment and Prevention Study: A real‐world community‐based trial of direct‐acting antivirals for hepatitis C among people who inject drugs	2
Global prevalence of occult hepatitis B: A systematic review and meta‐analysis	2
Global elimination of HBV: Is it really achievable?	2
Issue Information	2
Geographic variation in HCV treatment penetration among people who inject drugs in Baltimore, MD	2
Large‐scale screening is not useful for identifying individuals with hepatitis B or C virus infection: A prospective Swiss study	2
	2
Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community	2
Issue Information	2
Chronic hepatitis B beyond clinical burden: Psychosocial effects and impact on quality of life	2
Issue Information	2